Sign in
CompletedPhase 3

CMV preemptive therapy in high-risk immunocompetent major heart surgery patients. A multicenter, double blind, randomized, clinical trial (GAN-CAR).

Key facts

Who runs it
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
Where
Spain5 sites in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
226 people enrolled
Started
19 Sept 2023
Ended
7 Jul 2025
Type of study
Interventional
Record updated
20 December 2023

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Written informed consent must be obtained before any study-specific assessment is performed
  • Adult patients (≥18 years old)
  • Patients that underwent a MHS in the last 90 days prior to inclusion
  • Patients remaining in the ICU at least 72h after the surgery
  • Female patients of child-bearing potential must have a negative urine pregnancy test at screening and agree to use reliable methods of contraception upon enrolment according to the recommendations provided by CTFG, during the treatment period and for one month following the last dose of investigational drug
  • Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential) upon enrolment according to the recommendations provided by CTFG, during the treatment period, and for 3 months following the last dose of investigational drug
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Who cannot take part

  • Patients treated with antiviral drugs that are active towards CMV, such as, ganciclovir, valganciclovir, acyclovir, valacyclovir, famciclovir, cidofovir, letermovir, maribavir, brincidofovir) in the last week before inclusion
  • Patients participating in another clinical trial with an experimental drug
  • Patients with known hypersensitivity to valganciclovir, ganciclovir or any of the excipients
  • Immunocompromised patients: HIV positive infection, Neutropenia (neutrophile count <1000/mm3), Platelet count <25,000 U/µL, Hematopoietic transplant, Solid organ transplant needing immunosuppression, Chemotherapy received in the last 3 months prior to inclusion, Hereditary immunosuppression, Immunomodulatory drugs treatment (TNFα or rituximab) in the prior 3 months or alemtuzumab in the previous 6 months, Oral or intravenous (IV) corticosteroids treatment (>10 mg/day) in the last 30 days, Methotrexate treatment (≥10 mg/s) or azathioprine treatment (≥75 mg/s)
  • Females who are pregnant or breastfeeding
  • Patients whose life expectancy is 48-72h

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine the clinical impact of administering targeted pre-emptive antiviral therapy to high-risk (≥3 days in the cardiac surgery ICU and CMV viral load), immunocompetent adults, after MHS.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
20 December 2023